Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EARTH EXPLORER 1: Mavrilimumab in Moderate-to-Severe Rheumatoid Arthritis
NCT01706926Phase 2Completed
- Sponsor
- MedImmune
- Start
- Aug 2012
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 2 trial of mavrilimumab in rheumatoid arthritis (RA), sponsored by MedImmune. Started Aug 2012; status: completed.
02
Drugs
mavrilimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01706926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01706926.